Halopid

In low doses-
nervousness, anxiety states and associated psychic disorders as irritability gressiveness, psychic lability and insomnia
functional disorders caused by anxiety states such as trembling, thorax oppression, gastrointestinal hypermotility and digestive disorders
tics and stuttering
... Read more
In low doses-
nervousness, anxiety states and associated psychic disorders as irritability gressiveness, psychic lability and insomnia
functional disorders caused by anxiety states such as trembling, thorax oppression, gastrointestinal hypermotility and digestive disorders
tics and stuttering
nausea and vomiting
In higher doses-
psychomotor agitation in mania, dementia, acute and chronic schizophrenia, alcoholism
delusions and hallucinations in acute and chronic schizophrenia, acute confusion
choreatic movements
behavior and character disorders in children
tics and stuttering
vomiting

Tablet
-
Initial dose for adults-
Moderate symptomatology: 0.5 mg to 3.0 mg 2 to 3 times daily
Severe symptomatology: 3.0 mg to 5.0 mg 2 to 3 times daily
Elderly patients: 0.5 mg to 4.5 mg 2 to 3 times daily
Chronic or Resistant patients: 3.0 mg to 6.0 mg 2 to 3 times daily
Patients who remain severely disturbed or inadequately controlled may require dose adjustment. Daily dose upto 100 mg may be necessary in some cases to achieve optimal response.
Children: A suggested dose for the management of behaviour disorders in disturbed and schizophrenic children is 50 microgram per kg body weight.
Injection (intramuscular or intravenous)
-
Schizophrenia and other psychosis, mania:
Initially 2-10 mg, then every 4-8 hours according to response to total maximum 18 mg daily
Severely disturbed patients may require an initial dose of up to 18 mg
Elderly (or debilitated) initially half adult dose
For children not recommended.

G-G-Haloperidol is a safe neuroleptic. Headache, vertigo, insomnia are the more common side effects encountered. Drowsiness, lethargy, stupor, confusion, restlessness, agitation, anxiety, euphoria and exacerbation of psychotic symptoms including hallucinations also may occur. Dry mouth, blurred vision, urinary retention, heartburn, nausea, vomiting, anorexia, diarrhea and hypersalivation have also been reported.

G-G-Haloperidol may lower the convulsive threshold and has been reported to trigger seizures in previously controlled known epileptics. When instituting G-G-Haloperidol therapy in these patients, adequate anticonvulsant medication should be maintained concomitantly. As with other antipsychotic agents, G-G-Haloperidol should be administered cautiously to patients with severe impairment of liver or kidney function and to patients with known allergies or history of allergies to other neuroleptic drugs. Caution is also advised in patients with pheochromocytoma and conditions predisposing to epilepsy such as alcohol withdrawal and brain damage. Since the drug may have a possible potentiating effect on potent analgesics or hypnotics, caution is recommended when prescribing it to patients who are regularly treated with such drugs.

Haloperidol is a butyropherone derivative with antipsychotic properties that has been considered particularly effective in the management of hyperactivity, agitation and mania. Haloperidol is an effective neuroleptic and also possesses antiemetic properties. It may also exhibit hypothermic and anorexiant effects and potentiate the action of barbiturates, general anesthetics and other CNS depressant drugs. Haloperidol is a quick acting substance and has a duration of action of about 12 hours after one single administration. The optimum daily therapy consists of 2 administrations.